521980-82-5

Basic information

• Product Name: diMethyl 5-broMopyridine-2,3-dicarboxylate
• Synonyms: 2,3-Pyridinedicarboxylic acid, 5-bromo-, dimethyl ester (9CI);5-Bromo-2,3-pyridinedicarboxylic acid dimethyl ester
• CAS NO: 521980-82-5
• Molecular Formula: C₉H₈BrNO₄
• Molecular Weight: 274.06812
• Mol File: 521980-82-5.mol

Chemical Properties

• Boiling Point: 315.0±37.0 °C(Predicted)
• Appearance: /
• Density: 1.569±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: -3.18±0.10(Predicted)
• CAS DataBase Reference: diMethyl 5-broMopyridine-2,3-dicarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: diMethyl 5-broMopyridine-2,3-dicarboxylate(521980-82-5)
• EPA Substance Registry System: diMethyl 5-broMopyridine-2,3-dicarboxylate(521980-82-5)

Safety Data

• Hazardous Substances Data: 521980-82-5(Hazardous Substances Data)

Usage

Uses

Used in Organic Chemistry Synthesis:
DiMethyl 5-bromo-pyridine-2,3-dicarboxylate is used as a key intermediate in organic synthesis for its ability to participate in nucleophilic substitution reactions, where the bromine atom is replaced by a nucleophile. This property makes it valuable in the creation of new organic compounds and materials.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, DiMethyl 5-bromo-pyridine-2,3-dicarboxylate is used as a building block for the development of new drugs. Its unique structural features allow it to be incorporated into medicinal compounds, potentially leading to the discovery of novel therapeutic agents.
Used in Chemical Research:
DiMethyl 5-bromo-pyridine-2,3-dicarboxylate is also utilized in chemical research as a model compound to study various reaction mechanisms and to understand the behavior of pyridine derivatives under different conditions.
As an organic compound, DiMethyl 5-bromo-pyridine-2,3-dicarboxylate requires careful handling and appropriate safety measures to ensure the well-being of those working with it in laboratory and industrial settings.

Upstream product

• 67-56-1 methanol 
• 89-00-9 Pyridine-2,3-dicarboxylic acid 
• 98555-51-2 5-Bromo-pyridine-2,3-dicarboxylic acid 
• 605-38-9 dimethyl 2,3-pyridinedicarboxylate 

Downstream Products

• 1375541-21-1 (S)-2′-oxo-1′,2′,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3′-pyrrolo[2,3-b]pyridine]-3-carboxylic acid 
• 1374248-79-9 (6S)-N-[(3S,5S,6R)-5-(2-Fluoro-3-methylphenyl)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide 
• 1374248-80-2 (S)-N-((3S,5S,6R)-6-methyl-2-oxo-5-(o-tolyl)-1-(2,2,2-trifluoroethyl)piperidin-3-yl)-2’-oxo-l‘,2’,5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3’-pyrrolo[2,3-b]pyridine]-3-carboxamide 
• 1374248-77-7 (6S)-N-[(3S,5S,6R)-6-methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)piperidin-3-yl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide 
• 1613148-39-2 3-(1-(2-chloro-3,6-difluorophenyl)ethoxy)-5-(6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)pyridin-2-amine 
• 1613148-45-0 3-(1-(2-chloro-3,6-difluorophenyl)ethoxy)-5-(6-trityl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)pyridin-2-amine 
• 1613148-44-9 (6-trityl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)boronic acid 
• 1613148-38-1 N, N-bis(tert-butoxycarbonyl)-3-(1-(2,5-dichlorophenyl)ethoxy)-5-(6-trityl-6,7-dihydro-5H-pyrrolo[3,4-b]pyridin-3-yl)pyridin-2-amine 
• 905273-36-1 3-bromo-6,7-dihydro-5H-pyrrolo[3,4-b]pyridine 
• 905273-34-9 5-bromo-2,3-bis (bromomethyl) pyridine 
• 1356330-71-6 5-bromo-2,3-bis(hydroxymethyl)pyridine 

Relevant articles and documents

PYRROLIDINYL UREA DERIVATIVES AND APPLICATION THEREOF IN TRKA-RELATED DISEASES

The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and f

CGRP ANTAGONIST COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1a): and salts thereof, wherein W, Z, L, R1and R2 are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of disorders associated with CGRP receptors.

CGRP ANTAGONIST COMPOUNDS

The disclosures herein relate to novel compounds of Formula (1): and salts thereof, wherein A1, A2, Q, X, R1, R2 and R3 are defined herein, and their use in treating, preventing, ameliorating, control

Calcitonin gene-related peptide (CGRP) receptor antagonist treatment of migraine

Migraine is ranked as the sixth cause of years lost due to disability, with around 1.04 billion migraine sufferers globally. Triptans are considered the standard for acute migraine treatment, but an important number of migraineurs do not respond to them and these drugs are contraindicated in patients with cardiovascular disease. Migraine therapy is currently undergoing tremendous development, i.e., 5-HT1F receptor agonists (ditans), anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies, and small-molecule CGRP receptor antagonists (gepants). Ubrogepant (MK-1620) is a small-molecule, potent and selective CGRP receptor antagonist. In two phase III clinical trials (ACHIEVE I and II), ubrogepant showed, at 2 hours, significant percentages of pain freedom, and absence of the most bothersome symptoms in migraine patients. In a phase III study to assess the long-term (52-week) safety and tolerability, ubrogepant displayed good tolerability, and no signs of hepatic toxicity. In March 2019, the U.S. Food and Drug Administration accepted the new drug application (NDA) for ubrogepant for the acute treatment of migraine.

TARGETING COMPOUNDS

The disclosure provides, at least in part, liver, intestine and/or kidney-targeting compounds and their use in treating liver, intestine and/or kidney disorders, such as non-alcoholic steatohepatitis, alcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, and hepatitis B; and/or chronic kidney disease, glomerular disease such as IGA nephropathy, lupus nephritis, or polycystic kidney disease. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Substituted ring compound and its method and use thereof

The invention provides a substituted cyclic compound as well as a use method and application thereof. The compound is a compound as shown in a formula (I) or stereoisomers, stereomers, tautomers, nitric oxides, solvates, metabolites and pharmaceutically acceptable salts or prodrugs of the compound as shown in the formula (I). The invention further provides a medicament composition containing the compound. The compound and the medicament composition are capable of regulating the activity of protein kinase in a biological sample body and are used for protecting, treating or relieving proliferative diseases of patients. The formula (I) is as shown in the specification.

SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF USE

The present invention provides novel substituted alkynyl compounds, pharmaceutical acceptable salts and formulations thereof useful in modulating the protein tyrosine kinase activity, and in modulating cellular activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.

PYRIDINE CGRP RECEPTOR ANTAGONISTS

The present invention is directed to pyridine derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

ALIPHATIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS

The present invention is directed to aliphatic spirolactam derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which CGRP is involved, such as migraine. The invention is also directed to pharmaceutical\compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.

PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS

The present invention is directed to piperidinone carboxamide azaindane derivatives which are antagonists of CGRP receptors and useful in the treatment or prevention of diseases in which the CGRP is involved, such as migraine. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which CGRP is involved.